Introducing
JWC best-practice
guidance for
tissue regeneration
When wounds fail to respond to standard of care, often the only recourse is to use advanced therapies.
One example of an advanced therapy is biomaterials derived from human, animal, synthetic and biosynthetic sources, which can be used for the repair and regeneration of soft tissue. But there
are no universal guidelines on best practice
for the use of this technology.
Scroll
To address this, JWC has published an expert opinion consensus document:
Best practice for wound repair and regenerationuse of cellular, acellular and matrix-like products (CAMPs)
JWC International consensus document aims
Its aim is to improve understanding of the biological technologies — formerly known as skin substitutes and then cellular and/or tissue-based products (CTPs) — used in the repair and regeneration of soft tissue as part of wound management, and how best to use them.
The consensus document is based on a panel discussion by an international group of key opinion leaders. Its content was then scrutinised by an expert review board.
Goodbye CTPs,
say hello to CAMPs
Given the innovations in this technology in the
past two decades, the consensus document proposes that the term CTP should be replaced with a new one – cellular, acellular and matrix-like products (CAMPs) – to better reflect this.
The consensus panels support this with a new
all-encompassing definition of this therapy.
‘A broad category of biomaterials, synthetic materials or biosynthetic matrices that support repair or regeneration of injured tissues through various mechanisms of action.’
Definition of CAMPs
To understand more about the new categorisation, which is based on the product’s composition, watch here.
When to use CAMPs
CAMPs are one of an array of advanced therapies that can be used when a patient has not responded to standard of care. But how do you know when to select a CAMP, rather than another advanced therapy? Consider using CAMPs if you need to achieve one of the following outcomes:
Are CAMPs right for your patient?
To find out if – and when – your patient is suitable for CAMP application, follow this decision-tree, where the final goal is to achieve full wound closure and a return to optimal function. Click on the links for more details for the initial steps of the pathway.
Decision tree for CAMP application
Application
Always follow the CAMP manufacturer’s instructions for use when applying the product. But there are some principles that apply to all CAMPs, which need to be followed to achieve good outcomes.
Wound bed preparation with adequate debridement is essential to achieve a good outcome with CAMPs.
Safe but aggressive debridement of non-viable tissue is critical before application of any CAMP, regardless of aetiology.
During application, ensure there is full contact between the CAMP and the wound bed, with no dead spaces in which fluid can accumulate.
Provide patients with information and education on CAMPs before application.
The consensus panel strongly agrees that the use of CAMPs can help promote healing in wounds that have not responded to standard of care. They concluded with recommendations on how to get the best out of this technology, and what general innovations are needed to achieve wider acceptance and uptake of this technology.
Panel recommendations
Chair and authors
Review panel
Key
points
View panel recommendations
Download the
full document
Watch the
full webinar
on-demand
SUPPORTED BY
Webinar intro
1
2
3
4
5
6
7
8
9
Structural support for soft-tissue deficits, as well as a barrier against the external environment
1
2
3
4
5
6
8
9
1
Stimulation of angiogenesis and matrix production
Coverage of deep structures
3
4
5
6
7
8
9
Epithelial cell
migration
Binding/inactivation
of proteases and protection of endogenous growth factors
Enhancement of
surgical closure
Improvement in and maintenance of functional performance, such as joint range of motion and increased tensile strength
Reduced risk of
wound recurrence
Improved cosmetic appearance by minimising scar tissue
2
7
Get in touch Anthony Kerr, managing director, MA Healthcare Email anthony.kerr@markallengroup.com Tel +44 7979 520828